Skip to main content

Security report for dextenza.com

Ocular Therapeutix, Inc. · Healthcare · United States

Medium risk. 5 critical or high findings in Security headers, GDPR outside view and 1 other check.

Security score

69/100

Risk levelMedium

0–100, higher is better. How it is calculated

Ocular Therapeutix, Inc. operates the DEXTENZA website, promoting a corticosteroid ophthalmic insert for treating ocular inflammation and pain post-surgery. The company targets US healthcare professionals, providing detailed product information, safety data, and surgeon testimonials. The website reflects a specialized pharmaceutical business model with a focus on innovative drug delivery technology. Technically, the site is built on WordPress with modern libraries and SEO tools, delivering a professional and responsive user experience. Security posture is solid with HTTPS and basic security headers, though additional headers and explicit security policies could enhance protection. The absence of WHOIS data is a notable anomaly but does not detract from the site's professional presentation and trust signals. Overall, the site demonstrates good digital maturity and compliance with privacy regulations, supporting its credibility in the healthcare sector.

Scanned

NIS2 and GDPR posture

GDPR outside view
53/ 100 · Medium
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

5 findings rated critical or high. Fix these first.

  1. Security headers

    Security headers are instructions your web server sends to every visitor’s browser. Missing ones leave visitors more exposed to attacks such as clickjacking and injected scripts.

    • High

      Missing X-Frame-Options header

      Prevents clickjacking attacks

      What to do: Add "X-Frame-Options: DENY" or "X-Frame-Options: SAMEORIGIN"

  2. GDPR outside view

    These are the privacy signals visitors and data protection authorities look for under GDPR.

    • High

      No Cookie Policy found

      GDPR requires clear information about cookie usage

      What to do: Add a dedicated cookie policy explaining cookie usage and purposes

    • High

      No Cookie Consent Banner found

      GDPR requires explicit consent for non-essential cookies

      What to do: Implement a cookie consent banner that appears on first visit

  3. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1
    • High

      Weak SSL Key Length

      SSL certificate uses 256-bit key, which is considered weak

      What to do: Use at least 2048-bit RSA or 256-bit ECC key

      • CWE-326
      • OWASP A04:2025
      • Mozilla TLS: Mozilla Server Side TLS 6.0 intermediate: rsa_key_size 2048

Need hands-on remediation? Email guard@offseq.com

Keep watching dextenza.com

This scan found 22 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
47
Security headers
75
Email security
70
DNS health
70
Network security
100
GDPR outside view
53
Average
69

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

The company holds a niche position in ophthalmic pharmaceuticals, leveraging patented sustained-release drug delivery. Its business model centers on product sales supported by surgeon education and patient access programs. The website's content and structure indicate a medium-sized enterprise with a US base. The presence of pharmacovigilance contact details and comprehensive prescribing information underscores regulatory compliance. The marketing approach is professional, targeting healthcare providers rather than consumers, which aligns with pharmaceutical industry norms. The company maintains active social media presence on LinkedIn and Twitter, enhancing its professional outreach.

Security posture

The website employs HTTPS with a valid SSL configuration and includes standard cache-control headers. It uses Google Tag Manager and Analytics scripts loaded asynchronously, minimizing performance impact. However, the site lacks advanced security headers such as Content-Security-Policy and X-Frame-Options, which are recommended to mitigate common web vulnerabilities. No security.txt or explicit vulnerability disclosure pages were found, limiting transparency in incident response. The presence of pharmacovigilance reporting channels indicates some level of incident management related to product safety. Overall, the security posture is good but could be improved with additional headers and formal security policies.

Recommendations

  1. Implement advanced security headers including Content-Security-Policy, X-Frame-Options, and X-Content-Type-Options to enhance protection against common web attacks.
  2. Publish a dedicated security policy and vulnerability disclosure page to improve transparency and trust.
  3. Add a security.txt file at the root domain to facilitate responsible vulnerability reporting.
  4. Regularly monitor and update third-party scripts and libraries to avoid potential vulnerabilities.
  5. Enhance accessibility features to improve compliance with standards and user experience for all visitors.

Contact details published on the site

Addresses
Legal name
Ocular Therapeutix, Inc.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Ocular Therapeutix, Inc.
Description
DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg is a corticosteroid indicated for the treatment of ocular inflammation and pain following ophthalmic surgery.
Key services
Ophthalmic drug delivery, Patient access and support programs, Surgeon education and testimonials
Content quality
good
Branding
consistent

Technology

Stack
WordPress, Google Analytics, Google Tag Manager, Font Awesome, jQuery, Swiper, AnyChart
Frameworks
Yoast SEO
Platforms
WordPress CMS
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • No exposed sensitive data in HTML
  • Use of Google Tag Manager and Analytics with async loading

Analytics and tracking

Services
Google Analytics, Google Tag Manager
Tracking level
moderate
Privacy practices
good

Advertising

Transparency
basic

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is fully accessible with no blocking or WAF challenges.
  2. Content is targeted at US healthcare professionals with detailed product and safety information.
  3. Strong presence of regulatory and safety disclaimers consistent with pharmaceutical industry standards.
  4. Use of modern web technologies and SEO best practices.
  5. Contact information and pharmacovigilance reporting channels are clearly provided.
  6. No evidence of security policy or vulnerability disclosure page.
  7. WHOIS data missing, which reduces domain trust but website content is professional and consistent.
Technical notes

Notes

The website is built on WordPress CMS, utilizing modern front-end libraries such as jQuery, Font Awesome, Swiper, and AnyChart for interactive content. SEO is managed via Yoast SEO plugin, with well-structured metadata and JSON-LD schema for rich search results. Performance is moderate with asynchronous loading of analytics scripts. Mobile optimization is good, though accessibility features are basic and could be enhanced. No hosting provider information was detected. The site uses multiple Google services for analytics and tag management, indicating a mature digital marketing setup. Technical debt appears low, but security header implementation is incomplete.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with dextenza.com. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review dextenza.com.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.